Cancer immunology

drug development

novel diagnostic biomarkers

T cell lymphomas

cytokines

signal transduction

immune pathology and therapy

autoimmunity

allergy

transplantation

tumor immunology

cancer

Author of 270 papers in peer-reviewed journals and patents/patent applications within the fields of immunology, immune pathology, signal transduction and gene regulation.

Many publications in high (impact factor > 5) and very high (impact factor > 10) journals including Nature Immunol, Nature Commun, Blood, PNAS, Genes Dev, Cancer Res, Leukemia, and other

Sum of the times cited: > 8000

H-index: 52 (= number of articles cited more than 52 times)

Total number of peer-reviewed publications: > 270

Author of 35 publications, interviews, view-point ect. (not peer reviewed) in news papers and magazines, periodicals, and media like "Ingeniøren", "Ugeskrift for Læger", news and publications from "Kræftens Bekæmpelse", "HøjteknologiFonden", "Danmarks Radio", and other.

Made many scientific discoveries including identifying new HLA genes, their function and importance in transplantation and autoimmunity, unravelled Interleukin-2 signal cascades and pathological signalling in T cell lymphoma, discoveries of oncogenes and their targets and functions, diagnostic miRNA profiling of inflammatory skin disorders, identification of novel therapeutic targets, and other discoveries published in more than 270 international peer reviewed journals and patents (cf. above)

"Forskergruppeleder"

managing and financing a research group of 12-14 including associate and assistant professors, post docs and PhD students visiting scientists, as well as graduate students and technicians.

Project manager

Project manager of high-technology, drug and biomarker development, and other projects involving the University of Copenhagen, Exiqon, LEO Pharma, Zealand Pharma, and since January 2016 heading a “tandem-project” bridging basic and clinical health science and supported by the Novo Nordic Foundation, Kræftens Bekæmpelse and other sources with a total budget of 24 mill.

Organizer

Organizer and leader of an international collaboration on “Identification of novel therapeutic targets in T cell lymphoma” (DK, USA, Canada, Germany, Austria)

Organizer of an international study on “Bacterial toxins in colon inflammation and Cancer” (DK, UK, Italy, Sweden)

Instigator and inventor of a novel master education in Immunology and Inflammation at the Health Science Faculty. The education is unique as it is build around a close collaboration between the academic environment at the University and the majority of Pharmeceutical companies in the Greater Copenhagen area. The education was launched from September 2016.

14 PhD students including industrial PhDs

Supervised more than 110 master- and PhD students from UC and a series of industrial PhD students from Danish and International pharmaceutical and biotech companies.

Scientific advisor to Mindera Corp (San Francisco, CA) since January 2017. Member of the Scientific Advisory Board at Mindera Corp, a Californian based company developing novel micro-needle devices to human subjects and subsequent analysis by qPCR and RNA-Seq from skin.

Scientific collaboration with Mindera Corp, Novo Nordisk, H-Lundbeck, LEO Pharma, Bioneer, Exiqon, ALK-Abello and Zealand Pharma.

Participated in novel drug discovery and development with Zealand Pharma and other companies.

Ad hoc consultant on patent investigations to Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. New York, USA.

Consultant for Human Frontier Science Program, Strasbourg CEDEX, France, Imperial Cancer Research Foundation UK, and the Broad Association (USA). Previous Co-Editor for Exp Clin Immunogen and Advances in Hematology. Reviewer for multiple international journals and organizer/co-organizer of several International conferences. Key-note speaker and chairman of sessions on immune regulation/inflammation/lymphoma at international conferences. Since 2007 Expert assessor and consultant for the Research Council of Norway and ad hoc consultant to the Swedish-, Baltic-, and Dutch- research councils and the Dutch Cancer Research Council. Appointed member of the Danish Research Council – Forskningsrådet for Sundhed og Sygdom (FSS) for a 6 year period from 2013-2019. Member of the FSS executive committee from 2017-2018. From 2018-2022 appointed member of the Scientific Advisory Board (KBVU) for the Danish Cancer Society (Kræftens Bekæmpelse) and other private foundations.